Medicines Development Looks Different Than It Did Ten Years Ago. Here’s How the CMD Program Has Kept Pace.

Ask a pharmaceutical professional in 2015 to describe the fundamentals of medicines development, and the answer would have been fairly predictable. Clinical pharmacology. Regulatory frameworks. Trial design. Safety surveillance. These were the pillars, and they were stable. The roles within the development process were clearly defined. The expectations, largely known.

That world still exists — but it has been significantly complicated.

Over the past decade, medicines development has shifted in ways that are still playing out. Some of those shifts were gradual, the product of scientific advancement and regulatory evolution. Others were abrupt — the COVID-19 pandemic, for instance, compressed years of methodological change into a matter of months, forcing the industry to adapt faster than anyone anticipated. The result is a landscape that looks recognizably similar to what it was in 2015, but operates very differently.

For professionals working in this space, that gap between familiar and current is worth paying attention to.

The Shifts Worth Understanding

Take clinical pharmacology. The core science — how drugs behave in the body — has not gone anywhere. But the discipline now sits at the intersection of biomarker science, pharmacogenomics, and precision medicine in ways that were largely theoretical a decade ago. What was once a relatively contained area of expertise has become something considerably more complex, and considerably more consequential for development strategy.

Health economics has undergone perhaps the most dramatic repositioning. It used to be the thing you thought about toward the end of a development program, when it was time to build a market access case. That approach is now outdated. Payers and health technology assessment bodies have made clear that economic evidence needs to be part of the development narrative from early stages — not assembled at the end. Professionals who encounter health economics only as a late-stage handoff are working with an incomplete picture.

Clinical trial design has been transformed from multiple directions at once. Adaptive designs have given teams more flexibility to respond to emerging data. Real-world evidence has expanded the definition of what counts as clinical proof. Decentralized trials — accelerated by necessity during the pandemic — have changed assumptions about where research happens and who can participate. The confirmatory trial of today is a different instrument than it was in 2015, and the exploratory work that precedes it has changed just as much.

Regulatory science has kept pace with all of this, sometimes leading it. Accelerated pathways, expanded use of surrogate endpoints, patient-reported outcomes with real evidentiary weight — agencies around the world have been actively reshaping the frameworks that govern development. Navigating this environment now takes more than familiarity with the rules. It takes an understanding of the reasoning behind them.

Long-term safety has grown more complex in proportion to the growth of novel modalities. Biologics, cell and gene therapies, RNA-based medicines — each brings its own safety considerations, its own post-market surveillance requirements, its own evolving body of knowledge. The safety professional of 2026 is managing a fundamentally different portfolio of questions than their counterpart was in 2015.

And then there is the patient. This is perhaps the change that is hardest to quantify but easiest to feel. A decade ago, patient engagement was often treated as a communications exercise — something that happened adjacent to the science, not within it. That has changed. The patient voice now carries weight in protocol design, endpoint selection, and benefit-risk assessment. Regulatory agencies have made it an expectation. And Medical Affairs — once regarded primarily as a post-approval function — has emerged as the function best positioned to bridge clinical evidence and the real-world experiences of patients and healthcare providers.

These are not peripheral developments. They are changes to the fundamentals themselves.

How the CMD Program Has Responded

When the Certification in Medicines Development program launched in 2017, it was built around the enduring principles of the field — the scientific, regulatory, and economic frameworks that underpin how medicines reach patients. Nine years later, those principles are still at the core of the curriculum. What has changed is everything around them.

The CMD program has been continuously updated to reflect the field as it actually exists. Health economics is treated as foundational, not supplementary. Patient centricity is addressed as a competency, not a concept. Medical Affairs is examined as a strategic function with genuine influence on development outcomes. The curriculum does not teach the fundamentals as static knowledge to be catalogued — it teaches them as a framework that professionals need to understand deeply enough to apply in a landscape that keeps shifting.

Recognizing that fundamentals evolve encourages professionals to revisit and update their knowledge, ensuring they remain effective in a shifting field, and feel responsible for continuous learning.

What Module 1 Is There to Do

Module 1 of the CMD program is where that foundation gets built — or in many cases, rebuilt.

It covers clinical pharmacology, health economics, exploratory and confirmatory clinical development and clinical research, regulations, and long-term safety, providing a comprehensive understanding of how modern medicines development works and how these disciplines connect, which is essential for effective practice.

It is available as part of the full ten-month CMD certification or as a standalone module. That flexibility is intentional. Not every professional needs the full program at any given point in their career. Some need a specific module. Some want to start with a foundation and decide from there. The program is designed to accommodate both.

If you have been in the pharmaceutical industry for a while and have not revisited the fundamentals recently, revisiting Module 1 is worth a look because it emphasizes how much the field has evolved and how it can impact your current work.

Module 1 of the GMDP Academy Certification in Medicines Development program, in partnership with King’s College London, is available as a standalone module or as part of the full certification. Learn more: https://gmdpacademy.org/certification-programs/individual-modules/

Disclaimers

  • The material in these reviews is from various public open access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred